RyCarma is a clinical-stage biotech company developing first-in-class small molecule therapeutics for skeletal muscle and cardiovascular diseases
RyCarma is a clinical-stage biotech company developing first-in-class small molecule therapeutics for skeletal muscle and cardiovascular diseases. Our drug discovery platform is built from deep expertise on ryanodine receptors (RyRs), channels that regulate the intracellular flow of calcium ions in nearly all cell types.